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ABSTRACT
Overexpression of the oncofetal insulin-like growth factor 2 mRNA-binding 
protein 2 (IMP2/IGF2BP2) has been described in different cancer types. Gallbladder 
carcinoma (GBC) is a rare but highly aggressive cancer entity with late clinical 
detection and poor prognosis. 
The aim of this study was to investigate the role of IMP2 in human GBC. 
Tissue microarrays (TMAs) of an international multi-center GBC sample 
collection from n = 483 patients were analyzed by immunohistochemistry. IMP2 
immunoreactivity was found in 74.3% of the tumor samples on TMA, of which 14.0% 
showed strong and 86.0% low staining intensity. 72.4% of the tumor samples were 
IMP1 positive, but IMP1 showed lower expression in tumor tissue compared to control 
tissues. IMP3 immunoreactivity was observed in 92.7% of all tumors, of which 53.6% 
revealed strong IMP3 expression. Kaplan-Meier analysis linked high IMP2 expression 
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to shorter survival time (p = 0.033), whereas neither IMP1 nor IMP3 expression 
was linked to a decreased survival time. Eight different human biliary tract cancer 
(BTC) cell lines were evaluated for tumor growth kinetics in mouse xenografts. Cell 
lines with high IMP2 expression levels showed the fastest increase in tumor volumes 
in murine xenografts. Furthermore, IMP2 expression in these cells correlated with 
the generation of reactive oxygen species (ROS) and RAC1 expression in BTC cells, 
suggesting RAC1-induced ROS generation as a potential mechanism of IMP2-promoted 
progression of GBC.
In conclusion, IMP2 is frequently overexpressed in GBC and significantly 
associated with poor prognosis and growth rates in vivo. IMP2 might therefore 
represent a new target for the treatment of advanced GBC.
INTRODUCTION
Gallbladder carcinoma (GBC) is a lethal malignancy 
with a 5-year survival depending on tumor stages and being 
less than 10–20% in advanced tumors. The median survival 
time for patients with GBC is limited to one year [1]. 
This is mostly due to late diagnosis, thereby minimizing 
chances of cure. If diagnosed at early tumor stages (T1 
tumors), GBC can be cured in 61–100% [2]. Risk factors 
of GBC include chronic inflammation, gallstones, female 
gender, and high age. Complete surgical resection of the 
tumor is the only curative treatment. For unresectable 
GBC, chemotherapy is the only approved treatment 
strategy, but is only applied as a palliative therapeutic 
route with low efficacy. In spite of multiple studies on 
potentially attractive new diagnostic and therapeutic targets 
regarding GBC [3], the translation of these efforts in 
clinical management of GBC has been very limited so far. 
As a consequence, the identification and characterization 
of markers with diagnostic potential and significance is 
essential to stratify patients into different risk groups for 
GBC and to develop new therapeutic strategies.
The insulin-like growth factor 2 (IGF2) mRNA-
binding protein (IMP) IMP2/IGF2BP2 belongs to the 
family of three IMPs, namely IMP1-3. The IMP family 
member IMP3 has been shown to be of diagnostic and 
prognostic relevance in other biliary malignancies, e.g. 
pancreatobiliary malignancies and cholangiocellular 
carcinoma (CCC) [4, 5]. In a small study focusing 
on hepatocellular carcinoma (HCC), one out of two 
CCC samples showed overexpression of IMP2 [6]. 
Overexpression of IMP2 or of its splice variant p62 
(also known as IMP2-2 or IGF2BP2-2) was also 
reported for other tumor types, such as HCC, breast, 
lung, and esophageal cancer [7–13]. Moreover, a tumor-
promoting action of IMP2/p62 was described in HCC and 
glioblastoma (GBM) [9, 14].
Employing a comprehensive tissue microarray 
(TMA; n = 483) of human GBCs as well as a panel of 
eight biliary tract cancer (BTC) cell lines for xenograft 
and in vitro investigations, we here show that IMP2 
expression, but not IMP1 and IMP3 expression correlates 
with poor prognosis and in vivo xenograft tumor growth. 
RAC1-induced reactive oxygen species (ROS) generation 
might facilitate IMP2-induced tumor progression. 
RESULTS
Clinicopathological features
The cohort consisted of 341 female and 141 male 
patients and one sample with unreported gender. Survival 
periods between initial diagnosis and death were available 
for n = 397 patients. Tumor grade data were available for 
402 patients with 16% of GBCs cases were categorized 
as grade 1 (G = 1), 44% as grade 2 (G = 2), 39% as grade 
3 (G = 3), and 1% as grade 4 (G = 4). pT, pN, and M 
categories were available for 335, 147, and 128 patients, 
respectively. 15.5% of the cases were classified as pT = 1, 
40% as pT = 2, 35% as pT = 3, 8% as pT = 4, and 1.5% as 
carcinoma in situ (pTis). pN categories were distributed as 
follows: 55% pN0, 13% pN1, and 13% pN2 patients. 81% 
of the cases were classified as M0 and 19% as M1. The 
association between these clinicopathological parameters 
and survival is shown in Table 1.
IMP2/p62 expression, but not IMP1 and IMP3, 
correlates with tumor grade and lymphovascular 
invasion
Immunohistochemical staining revealed an 
exclusively cytoplasmic localization of IMP2/p62. 
Nuclear expression of IMP2/p62 was absent in all cases 
confirming the expected localization [15]. 25.7% of the 
cases were negative for IMP2/p62 expression, whereas 
from 74.3% positive samples 86.0% showed low IMP2/
p62 expression and 14.0% highly expressed IMP2/p62 
(Figure 1A) without being frequently mutated: mutations 
in the IGF2BP2 gene were observed in 1.35% of GBC 
cases investigated (n = 74) and in 0% of bile duct cancer 
samples (n = 294) (Sanger Institute COSMIC website, 
http://www.sanger.ac.uk/cosmic). Interestingly, IMP2/
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p62 staining intensity as well as total immunostaining 
(TIS) score correlated with high tumor grade (G3/4) and 
lymphovascular invasion (L1) (Table 2). A trend for a 
correlation with higher staining intensity and TIS scores 
was found without reaching statistical significance for the 
following parameters: high tumor stage (pT3/4), distant 
metastasis (M1), and vascular invasion (V1) (Table 2). 
72.4% of the tumor samples were IMP1 positive, 
however, IMP1 showed lower expression in tumor tissue 
compared to control tissues (p < 0.001) (Supplementary 
Figure 1A). IMP1 staining intensity inversely correlated 
with tumor grading (Supplementary Table 1). Both 
staining intensity and TIS score of IMP1 immunostaining 
negatively correlated with the presence of lymph node 
metastasis (N1), distant metastasis (M1), vascular invasion 
(V1), and lymphovascular invasion (L1) (Supplementary 
Table 1). 
IMP3 immunoreactivity was observed in 92.7% 
of all tumors, of which 53.6% revealed strong IMP3 
expression (Supplementary Figure 2A). IMP3 did not 
correlate with any of the investigated clinicopathological 
parameters (Supplementary Table 2). 
High IMP2/p62 expression is linked to short 
survival and p62 enhances tumor growth in vivo
Kaplan-Meier analysis of high versus low IMP2/
p62 expressing samples revealed a significantly reduced 
survival in patients with high TIS score (p = 0.033; 
Figure 1B). Furthermore, high staining intensity tended to 
be linked to short survival (p = 0.076; Figure 1C). Staining 
intensity of IMP1 expression (p = 0.019; Supplementary 
Figure 1B) but not TIS score (p = 0.122; Supplementary 
Figure 1C) correlated with longer survival time. IMP3 
expression was not linked to survival time (Supplementary 
Figure 2B, 2C). 
In order to investigate the effect of IMPs on tumor 
formation we employed a murine xenograft model with 
eight different BTC cell lines: five bile duct cancer cell 
lines [CC-SW-1 (Grade 2), BDC (Grade 4), EGI-1 (Grade 
3), Sk-ChA-1 (Grade 3), TFK-1 (Grade 2)] and three 
gallbladder cancer cell lines [Mz-ChA-1 (Grade 1), Mz-
ChA-2 (Grade 2), GBC (Grade 1)] [16]. Seven out of the 
eight BTC cell lines were tumorigenic, while CC-SW-1 cells 
did not grow at all in nude mice. Of note, IMP2 expression 
Table 1: Clinicopathological characteristics of GBC patients
 n survival
Gender  p-value
male 107  
female 290 0.78
Grade   
low (G1/2) 233  
high (G3/G4) 151 < 0.001
Tumor stage (pT)   
low (pT1/2) 199  
high (pT3/4) 165 < 0.001
Lymph node metastasis (pN)   
absent 75  
present 71 < 0.001
Metastasis (M)   
absent 99  
present 35 < 0.001
Vascular invasion (V)   
absent 86  
present 33 < 0.001
Lymphovascular invasion (L)   
absent 86  
present 59 < 0.001
Oncotarget89739www.impactjournals.com/oncotarget
and expression of its splice variant p62 were highest in 
cell lines originating from less differentiated metastases 
or metastasizing primary tumors: EGI-1, Mz-ChA-2, and 
Sk-ChA-1 [17, 18] (Figure 2A–2C). EGI-1 and Mz-ChA-2, 
both cell lines highly expressing IMP2 and p62 (Figure 
2A), showed the fastest tumor growth in vivo (Figure 2D, 
2E). Tumor growth significantly correlated only with p62 
expression (Figure 2F). Correlation with cell cycle data 
[19] revealed that IMP2/p62 expression in the BTC cell 
lines positively correlated with cells in the S, G2, and SG2 
phase, whereas a negative correlation was found with cells 
in the G0/G1 phase (data not shown). Interestingly, also two 
excised, patient-derived cholangiocarcinoma xenografts 
were analyzed and revealed strong IMP2 and p62 expression 
and a distinct tumor growth (Supplementary Figure 3). 
Neither tumor expressed IMP1 and only one of the tumors 
expressed IMP3 (Supplementary Figure 3A).
IMP2 and p62 expression are associated with 
RAC1 expression and ROS generation
Since p62 has been described to induce a more 
advanced tumor phenotype by promoting RAC1-induced 
ROS generation [9], RAC1 mRNA expression was 
measured in the eight BTC cell lines. We observed that 
RAC1 levels highly correlated with IMP2 mRNA and 
IMP2 protein as well as p62 protein levels (Figure 3A, 
3B). Of note, IMP1 protein levels also correlated with 
RAC1 expression. In order to test the significance of 
IMP2/p62-RAC1 correlation ROS levels were measured 
in the BTC cell lines. IMP2 and p62 mRNA and protein 
expression in the BTC cell lines were linked to an 
increased ROS production (Figure 3A, 3B). Also IMP1 
protein and IMP3 RNA expression were associated with 
increased ROS production.
Figure 1: IMP2 expression correlates with short survival and in vivo tumor growth. (A) Representative immunostainings 
against IMP2 in human GBC. Magnification: 20× and 50×. (B, C) Kaplan-Meier survival plots referring to low and high IMP2 expression 
levels in human GBC determined by TIS score (TS) (B) and staining intensity (I) (C). 
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DISCUSSION
A splice variant of the IMP2 gene, p62/IMP2-2, 
was originally identified as a tumor-associated auto-
antigen with auto-antibodies against p62/IMP2-2 detected 
in HCC patients [13] and in several other cancer types 
[11, 12, 20]. Recently, IMP2 knockout mice were 
suggested to exhibit resistance towards malignancy 
[21], while p62/IMP2-2 transgenic mice were reported 
to be more prone to hepatocarcinogenesis showing a 
more aggressive HCC phenotype [9]. Despite one study 
presenting IMP2 expression in one out of two investigated 
cases of CCC [6], nothing is known about the role of IMP2 
in biliary tract cancers. To the best of our knowledge, this 
is the first study based on a sufficient sample size, which 
correlates IMP2/p62 expression with tumor progression or 
patient survival in GBC.
In around 80% of GBC patients their cancer has 
infiltrated adjacent organs or has spread to distant sites 
at the time of diagnosis. This is due to the fact that 
early symptoms are rather non-specific, and effective 
biomarkers for GBC diagnosis are lacking. The same is 
true for prognostic markers of GBC progression. Although 
the prognostic relevance of several tissue biomarkers 
has been studied, none of them has made it as routine 
screening into the clinics so far [22]. 
Our immunohistochemical analysis of the largest 
human GBC collection we are aware of clearly showed 
that high IMP2/p62 expression is associated with 
advanced tumors and short survival. However, IMP3, 
which has been suggested as a diagnostic marker in GBC 
[23], did not correlate with prognosis in our study. In 
contrast, although IMP1 is known to be overexpressed and 
to promote tumor growth in HCC [24], IMP1 expression 
was associated with a rather better prognosis in GBC. 
IMP2/p62 expression has been reported to correlate with 
poor prognosis in other cancer entities such as HCC, 
glioblastoma (GBM), head and neck cancer, breast, and 
esophageal cancer [7, 8, 10, 14, 25]. Similarly, in vitro 
IMP2 expression was strongest in BTC cells originating 
from adenocarcinoma metastasis or metastasizing primary 
adenocarcinomas characterized by low differentiation 
underlining the correlation with poor outcome. The 
enhanced tumor growth of xenografts of cell lines highly 
expressing IMP2 suggests a tumor-promoting action of 
IMP2 in GBC. In hepatocarcinogenesis, IMP2 has been 
shown to facilitate tumor development [9], underlining the 
results of our study.
However, it is not clear how upregulation or aberrant 
expression of IMP2/p62 contributes to the neoplastic 
process in GBC. IMP2/p62 has been shown to induce ROS 
generation by an enhanced activation of the small GTPase 
Table 2: Association between IMP2 protein expression and tumor grades and stages
IMP2 
Intensity   TIS  
low high p-value  low high p-value
Grade        
low (G1/2) 195 11 179 27  
high (G3/4) 109 20 0.0018  90 39 < 0.001
Tumor stage (pT)        
low (T1/2) 156 17 141 32  
high (T3/4) 132 11 0.51  111 32 0.39
Lymph node metastasis (pN)        
absent 67 3 60 10  
present 64 4 0.67  60 8 0.66
Metastasis (M)        
absent 91 3 85 9  
present 28 2 0.40  26 4 0.056
Vascular invasion (V)        
absent 79 2 74 7  
present 27 3 0.089  24 6 0.098
Lymphovascular invasion (L)        
absent 79 2 74 7  
present 48 6 0.037  43 11 0.0495
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RAC1 due to increased expression of the paracrine factor 
DLK1 [9]. The correlation of IMP2 with RAC1 and ROS 
levels suggests the existence of a similar mechanism in 
GBC. RAC1 itself has been linked to poor prognosis and 
short survival in GBC [26]. Another pathway that might 
involve miR-1275, which has been described to target 
IMP2 [27] and is downregulated in GBC [28]. In GBMs 
IMP2 was shown to regulate oxidative phosphorylation, 
thereby affecting clonogenicity and tumorigenicity [14]. 
Furthermore, IMP2 was suggested to contribute to breast 
cancer progression by increasing cell migration and 
reducing cell adhesion to extracellular matrix proteins 
[29]. This is in line with the correlation of IMP2 and 
RAC1 expression, since RAC1 is also an important factor 
for cell migration [30, 31]. Still, further studies will be 
needed to shed light on the exact mechanisms by which 
IMP2/p62 is able to promote GBC progression. 
In summary, this study shows for the first time a 
correlation between patient survival as well as tumor 
progression and IMP2/p62 expression in GBC, which 
might involve RAC1-induced ROS production.
MATERIALS AND METHODS
Cohort for TMA
Formalin-fixed, paraffin-embedded gallbladder 
tissue samples and the corresponding clinical data 
were collected for 483 GBC patients from the Medical 
University of Innsbruck (12%), University Hospital of 
Seoul (23%), General Hospital Graz West (7%), and the 
Medical University of Graz (58%). The tissue samples 
were used for generating TMAs for further analyses. Due 
to the limited amount of tissue, staining of all samples 
Figure 2: IMP2 expression is linked to in vivo tumor growth. (A) Expression of IMP1, IMP2 and its splice variant p62 as well 
as IMP3 in eight different BTC cell lines analyzed by qPCR (A) and Western blot (B, C). (B) Representative Western blot showing IMP1, 
IMP2, p62, and IMP3 expression. (C) Signal intensities normalized to tubulin are shown (n = 3, 1–3 replicates). (D, E) Tumor growth of 
murine xenografts of the respective human BTC cell line (n = 2 each). Data are shown as mean ± SEM. (F) Correlation analysis between 
IMP2/p62 expression and tumor growth.
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could only be realized for IMP2/p62. For IMP1 and IMP3, 
a lower sample number was used for exploratory analyses 
(n = 350 and n = 179, respectively). 
Samples and data from the University Hospital of 
Graz and the General Hospital Graz South West used in 
this project were provided by the Biobank Graz under the 
permission of the ethics commission (EK number 24-177 
ex 11/12). In addition, authorization was given by the 
institutional review board of the Severance Hospital (no. 
4-2014-0421), and the requirement for informed consent 
was waived. A small part of gallbladder cancer samples 
(the study cohort from the University Hospital Innsbruck) 
was already utilized in a previous study [32] for which it 
was approved by the institutional review board. 
All corresponding haematoxylin/eosin (H/E) slides 
were centrally reviewed for confirmation of diagnosis 
and adequacy of material by an experienced and board 
certified pathologist (JH). 
Immunohistochemistry
Immunohistochemical stainings were performed 
using the Dako Envision AEC Kit (#K4009, Dako, 
Germany) for antibody detection according to the 
manufacturer’s instructions. Anti-IMP1 antibody (Santa 
Cruz), anti-IMP2/p62 antibody [10] detecting both 
isoforms, and anti-IMP3 antibody (Proteintech) were 
incubated for 1 h at room temperature. 
Immunohistochemistry (IHC) was analyzed by 
two independent investigators (JH and SMK) by light 
microscopy. The density and intensity of each core was 
semi-quantitatively scored (intensity 0 = no detectable 
staining, 1 = weak staining, 2 = moderate staining, and 
3 = strong staining) and differentiated in nuclear and 
cytoplasmic staining. Density was scaled as 0 for no IHC 
staining, 1 < 10%, 2 = 10-49%, 3 = 50-80%, and 4 > 80%. 
For analyzing the data total immunostaining scores (TIS) 
were calculated by multiplying density and intensity, 
and the groups were summarized in no staining (0), low 
staining (1), and high staining (2 and 3).
Non-tumor gallbladder tissue (n = 38) and 
secondary antibody only control were used as controls in 
immunohistochemistry.
Homovanillic acid assay 
H2O2 levels were measured using the homovanillic 
acid (HVA) assay as described previously [33]. 250,000 
cells per well were seeded in a 6-well plate. After 24 h 
cells were washed two times with 1xPBS and freshly 
prepared HVA solution (100 µM HVA, 4 U/ml horse-
radish peroxidase, dissolved in PBS containing Ca2+ and 
Mg2+, all from Sigma Aldrich) was added. In order to 
stimulate H2O2 production cells were treated with 0.1 µM 
phorbol 12-myristate 13-acetate (PMA) (Calbiochem) for 
5 min before the HVA solution was added. Cells were then 
Figure 3: Correlation of IMP2 expression with RAC1 expression and ROS generation. (A) Expression of RAC1 in eight 
different BTC cell lines analyzed by qPCR. (B) Correlation analysis between IMP expression and ROS levels and RAC1 mRNA levels. 
ROS levels (fold H2O2) are displayed as fold change of PMA-stimulated cells compared to untreated control. 
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incubated for 2 h at 37°C. 40 µl HVA stop buffer (0.1 M 
glycine, 0.1 M NaOH, 25 mM EDTA in water, all from 
Sigma Alderich) were added to each well of a black 96-
well plate, and 260 µl of the extracellular HVA supernatant 
were added. The fluorescence (312 nm excitation, 420 
nm emission) was then determined using a SpectraMax 
M5e (Molecular Devices). For the determination of the 
H2O2 concentration, a dilution series of H2O2 (0-5 µM) 
was treated the same way as described above. For protein 
quantification a BCA assay was performed.
Gene expression analysis
Total RNA was isolated from untreated cells 24 h 
after seeding in 3 cm petri dishes using TRIzol Reagent 
(Life Technologies, Vienna, Austria) and Direct-zolTM 
RNA MiniPrep Kit (Zymo Research, Irvine, California, 
USA) according to the manufacturer’s instructions. 
cDNA synthesis was performed with 1.0 µg total RNA 
per sample using the GoScriptTM Reverse Transcription 
System (Promega, Mannheim, Germany) and gene 
expression was analyzed using GoTaq qPCR Master 
Mix (Promega) on a ViiA7 real-time PCR system 
(Applied Biosystems, Life Technologies). All samples 
were measured in biological triplicates and technical 
quadruplicates within the PCR runs. Melting curve 
analysis was done to ensure the specificity of primers. Ct 
values were normalized to the housekeeping genes beta-
actin (actb) and beta-2-microglobulin (b2m). KiCqStart™ 
Primers for IMP1, IMP2 (full length; IGF2BP2_3) and 
IMP2-2/p62 (IGF2BP2_1), IMP3, RAC1 as well as the 
housekeeping genes were purchased from Sigma Aldrich 
(Vienna, Austria). Primer sequences were the following: 
ACTB_fwd: GACGACATGGAGAAAATCTG; 
ACTB_rev: ATGATCTGGGTCATCTTCTC; B2M_
fwd: AAGGACTGGTCTTTCTATCTC; B2M_rev: 
GATCCCACTTAACTATCTTGG; IGF2BP3_1_fwd: 
GGAGGAGATCATGAAGAAAATC; IGF2BP3_1_rev: 
TTTCTGATTGCTCAAACTGC; IGF2BP2_1_fwd: 
CATATACAACCCGGAAAGAAC; IGF2BP2_1_rev: 
CTCTGGATAAGAGTGATGATG; IGF2BP2_3_fw: 
CGGGTAGATATCCATAGAAAAG; IGF2BP2_3_rev: 
GAATCTCTTCGGCTAGTTTG; IGF2BP1_3_fwd: 
AGATAGACGTGCATAGGAAG; IGF2BP1_3_
rev: GTGTCCTTAGCCTCTTTATG; RAC1_fwd: 
TTGGTGCTGTAAAATACCTG; RAC1_rev: 
GGCATTTTCTCTTCCTCTTC.
Western blot
Western blots were performed as previously 
described [10]. Antibodies used were specific to IMP1 
(Santa Cruz), IMP2/p62 [6, 10] detecting both isoforms, 
IMP3 (Proteintech), and α-tubulin (#T9026, Sigma, 
Germany). IRDye680-conjugated anti-rabbit IgG (LiCor 
Bioscience, Germany) and IRDye800-conjugated anti-
mouse IgG (LiCor) were used as secondary antibodies. 
Signal intensities were determined by using the Odyssey 
infrared imaging system (LiCor).
Xenograft models
Eight different human BTC cell lines were tested 
for tumorigenicity in immunodeficient NMRI nude mice 
(TFK-1: metastasized extrahepatic biliary adenocarcinoma, 
EGI-1: extrahepatic biliary adenocarcinoma, Mz-
ChA-1: gallbladder adenocarcinoma abdominal wall 
metastasis, Mz-ChA-2: gallbladder adenocarcinoma liver 
metastasis, Sk-ChA-1: malignant ascites in extrahepatic 
biliary adenocarcinoma, BDC: bile duct cancer, CC-
SW-1: intrahepatic biliary adenocarcinoma, GBC: 
gallbladder mucosal carcinoma [19]). Tumor cells (107 
cells in 50 μl medium mixed with 50 μL Matrigel™ 
Basement Membrane Matrix (Dulbecco)) were injected 
subcutaneously into the left flank of two NMRI nude 
mice (Taconic, Bomholdtgard, Denmark) per cell line, 
respectively. Cells were cultured in Dulbecco›s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal 
calf serum in 5% CO2 at 37°C. All animal procedures were 
performed in accordance with the local animal welfare 
committee (Gen0030/15).
Tumor size (length x width) was measured by 
calipers once weekly for up to 125 days. Individual tumor 
volumes (V) were calculated by the formula: V = (length 
x [width]²)/2.
Statistics
For statistical evaluations, the immunohistochemical 
staining intensities were grouped as low (scores 0–1) and 
high (scores 2–3). Associations between binary categories 
were analyzed using the Chi²-test.
The data were stored in a relational scheme in the 
PostgreSQL 9.1 database management system. R and 
R-Studio with the R PostgreSQL package were used 
for calculations, Kaplan-Meier survival estimates were 
generated by the R Survival Package. The likelihood 
ratio test in Cox regression analysis was used to calculate 
p-values. In case of ties, the Breslow method was applied. 
Correlation analysis between expression levels 
of IMPs and xenograft tumor growth characteristics, 
RAC1, and ROS levels were performed using Pearson’s 
correlation and IBM SPSS v21 (Vienna, Austria).
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